762285-45-0Relevant academic research and scientific papers
MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO
-
Page/Page column 34, (2008/06/13)
Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure of formula (I) including pharmaceutically acceptable salts, esters, solvates, stereoisomers, and prodrugs thereof, wherein m, n, Q1, Q2, R1, R2, R3, R4, R7 and X are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.
Bis(aminopyrrolidine)-derived ureas (APUs) as potent MCH1 receptor antagonists
Grey, Jonathan,Dyck, Brian,Rowbottom, Martin W.,Tamiya, Junko,Vickers, Troy D.,Zhang, Mingzhu,Zhao, Liren,Heise, Christopher E.,Schwarz, David,Saunders, John,Goodfellow, Val S.
, p. 999 - 1004 (2007/10/03)
Ureas derived from two substituted 3-aminopyrrolidine subunits were prepared as constrained analogs of a linear lead compound and tested as antagonists of the MCH1 receptor. The series was optimized for substitution and stereochemistry to generate a functional antagonist with a Ki of 3.3 nM and IC50 of 12 nM (GTPγS).
MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO
-
Page 30, (2010/02/08)
Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, X, R1, R2, R3, R4, and R5 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.
